Pharmaceutical Health Services Research, School of Pharmacy, University of Maryland, Baltimore, Maryland, USA.
Child Adolesc Psychiatry Ment Health. 2008 Sep 25;2(1):26. doi: 10.1186/1753-2000-2-26.
The study aims to compare cross-national prevalence of psychotropic medication use in youth.
A population-based analysis of psychotropic medication use based on administrative claims data for the year 2000 was undertaken for insured enrollees from 3 countries in relation to age group (0-4, 5-9, 10-14, and 15-19), gender, drug subclass pattern and concomitant use. The data include insured youth aged 0-19 in the year 2000 from the Netherlands (n = 110,944), Germany (n = 356,520) and the United States (n = 127,157).
The annual prevalence of any psychotropic medication in youth was significantly greater in the US (6.7%) than in the Netherlands (2.9%) and in Germany (2.0%). Antidepressant and stimulant prevalence were 3 or more times greater in the US than in the Netherlands and Germany, while antipsychotic prevalence was 1.5-2.2 times greater. The atypical antipsychotic subclass represented only 5% of antipsychotic use in Germany, but 48% in the Netherlands and 66% in the US. The less commonly used drugs e.g. alpha agonists, lithium and antiparkinsonian agents generally followed the ranking of US>Dutch>German youth with very rare (less than 0.05%) use in Dutch and German youth. Though rarely used, anxiolytics were twice as common in Dutch as in US and German youth. Prescription hypnotics were half as common as anxiolytics in Dutch and US youth and were very uncommon in German youth. Concomitant drug use applied to 19.2% of US youth which was more than double the Dutch use and three times that of German youth.
Prominent differences in psychotropic medication treatment patterns exist between youth in the US and Western Europe and within Western Europe. Differences in policies regarding direct to consumer drug advertising, government regulatory restrictions, reimbursement policies, diagnostic classification systems, and cultural beliefs regarding the role of medication for emotional and behavioral treatment are likely to account for these differences.
本研究旨在比较不同国家青少年使用精神药物的流行率。
对来自 3 个国家的参保者在 2000 年的基于行政索赔数据的精神药物使用情况进行了一项基于人群的分析,涉及年龄组(0-4、5-9、10-14 和 15-19 岁)、性别、药物亚类模式和伴随使用。这些数据包括 2000 年来自荷兰(n=110944)、德国(n=356520)和美国(n=127157)的 0-19 岁的参保青少年。
美国(6.7%)青少年使用任何精神药物的年患病率显著高于荷兰(2.9%)和德国(2.0%)。抗抑郁药和兴奋剂的流行率是美国比荷兰和德国高 3 倍以上,而抗精神病药的流行率高 1.5-2.2 倍。非典型抗精神病药亚类仅占德国抗精神病药使用的 5%,而占荷兰的 48%和美国的 66%。不太常用的药物,如α激动剂、锂和抗帕金森药物,通常遵循美国>荷兰>德国青少年的排名,荷兰和德国青少年的使用非常罕见(<0.05%)。虽然很少使用,但荷兰青少年使用抗焦虑药的频率是美国和德国青少年的两倍。在荷兰和美国青少年中,催眠药的使用频率是抗焦虑药的一半,在德国青少年中则非常罕见。伴随药物使用在 19.2%的美国青少年中应用,是荷兰青少年的两倍多,是德国青少年的三倍多。
美国和西欧青少年以及西欧内部的精神药物治疗模式存在显著差异。这些差异可能归因于关于直接面向消费者的药物广告、政府监管限制、报销政策、诊断分类系统以及关于药物在情绪和行为治疗中作用的文化观念等方面的政策差异。